The global nuclear medicine market is expected to grow significantly from USD 21.3 billion in 2025 to USD 55.8 billion by 2035, representing a compound annual growth rate (CAGR) of 10.1%. Diagnostics will dominate this market with a 76.6% share, and urology is anticipated to lead the application segment with a 22.6% share. This growth is being driven by the rising demand for molecular imaging, advanced theranostic therapies, personalized cancer treatments, and technological innovations in radiopharmaceuticals, such as hybrid imaging systems and AI-powered analysis tools. The market is characterized by an increase in cancer incidence and the corresponding need for sophisticated diagnostic and therapeutic solutions, particularly in oncology. Major growth regions include China (12.4% CAGR), India (11.7% CAGR), and the USA (10.9% CAGR), among others. These countries are investing in nuclear medicine infrastructure, advanced diagnostics, and treatment methodologies. The nuclear medicine sector is witnessing innovative approaches, particularly in the use of targeted therapies for conditions such as prostate cancer and cardiology applications, showcasing a shift toward personalized treatment protocols. The competition in the market is intense, with established manufacturers focusing on developing advanced radiation therapies and maintaining compliance with regulatory standards to enhance patient outcomes.
Sat, 29 Nov 2025 08:11:35 GMT | Fact.MR